Braftide, with the CAS number 2411851-64-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule and is often studied for its role in targeting specific biological pathways. The compound is known for its ability to modulate certain cellular processes, which may have implications in the treatment of various diseases, including cancer. Braftide's structure typically includes functional groups that enhance its bioactivity and solubility, making it suitable for pharmacological studies. Additionally, its mechanism of action may involve interactions with specific proteins or enzymes within the body, leading to altered signaling pathways. As with many compounds in drug development, the safety profile, efficacy, and pharmacokinetics of Braftide are critical areas of research, and ongoing studies aim to elucidate its full potential in clinical applications.

Braftide

2411851-64-2: Braftide, with the CAS number 2411851-64-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. It is classified as a small molecule and is often studied for its role in targeting specific biological pathways. The compound is known for its ability to modulate certain cellular processes, which may have implications in the treatment of various diseases, including cancer. Braftide's structure typically includes functional groups that enhance its bioactivity and solubility, making it suitable for pharmacological studies. Additionally, its mechanism of action may involve interactions with specific proteins or enzymes within the body, leading to altered signaling pathways. As with many compounds in drug development, the safety profile, efficacy, and pharmacokinetics of Braftide are critical areas of research, and ongoing studies aim to elucidate its full potential in clinical applications.

<p>Braftide is an allosteric inhibitor of BRAF kinase that exerts its effect by targeting the surface of BRAF kinase dimers, thereby preventing their formation. It inhibits both wild-type BRAF and oncogenic BRAFG469A, with IC50 values of 364 nM and 172 nM, respectively. When combined with the TAT sequence, Braftide can suppress the MAPK signaling pathway, inhibiting the proliferation of KRAS-mutant tumor cells, with EC50 values of 7.1 μM for HCT116 and 6.6 μM for HCT-15.</p>

CAS 2411851-64-2

Braftide

Braftide

Ref: TM-TP2695